《滬深兩市》A股三大指數半日升0.3%至0.6% 中藥股走強 CRO概股急挫
國務院總理李克強主持召開國務院專題會議,表示繼續出台穩經濟階段性政策,要能用盡用及快出快落地。內地昨日(12日)新增本土確診病例188例,新增本土無症狀感染者727例。人行今日(13日)開展20億元人民幣(下同)7天期逆回購操作,單日淨回籠20億元,利率持平於2%。人民幣兌美元中間價今上調170點。A股三大指數高開後反覆靠穩。
上證半日升10點或0.3%,報3,272點;深成指升75點或0.6%,報11,952點;創業板指數升7點或0.3%,收報2,555點。上證、深成及創板半日成交分別為2,176億元、2,832億元及842億元。
中資金融股工行(601398.SH)及建行(601939.SH)分別升0.5%及0.4%。
CRO概念股受壓,藥明康德(603259.SH)跌停。康龍化成(300759.SZ)及泰格醫藥(300347.SZ)分別挫12.6%及8.7%。昭衍新藥(603127.SH)跌3.9%。
中藥股走強,龍津藥業(002750.SZ)及青海春天(600381.SH)漲停。雲南白藥(000538.SZ)、同仁堂(600085.SH)升1.4%至1.7%。
汽車股造好,比亞迪(002594.SZ)升1.6%。廣汽(601238.SH)及長汽(601633.SH)分別升3.1%及2.9%。
寧德時代(300750.SZ)升0.8%。天齊鋰業(002466.SZ)及贛鋒鋰業(002460.SZ)分別升1.5%及0.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.